Proven success with high-value and difficult targets
OmniAb offers computationally powered antigen design for production of challenging therapeutic targets. The antigen platform produces full-length membrane proteins, including multi-Tm proteins such as ion channels and G protein-coupled receptors (GPCRs), the largest class of therapeutic drug targets.
Antigen production works in tandem with our therapeutic antibody discovery platform, providing access to high-quality, functionally validated membrane protein antigens for immunization campaigns.
Multi-faceted antigen design leverages years of experience and a range of technologies.
Guided by molecular modeling and protein design capabilities, our antigen solutions team manages the cloning, expression, purification, reconstitution, and quality control of purified native-conformation membrane proteins for immunization and screening purposes.
Designer antigens to stimulate the right immune response
Antigens can be prepared in particular conformations with protein or small molecule conformational chaperones. The range of accessible protein antigen formats maximizes the chance of success in generating robust immune responses with desired specificities from any of the OmniAb antibody platforms.
Important factors you should take into consideration
There are a number of factors to keep top of mind when engaged in antigen design for antibody discovery.
For example, how complex is the antigen? This will affect how complex the antibody will be.
Another issue is what host animal is being used, such as rats, mice, or chickens. They all deliver a different mix of antibodies.
It’s also important to consider the nature of the application you need the antigens for and what is the most appropriate sequence involved in reaching your antigen goal. Above all, you want to keep out of the mix any epitopes that won’t work because of how they are structured.
We will be happy to consult with you if you have concerns or questions about the constraints involved in designing antigens.
Why you should choose OmniAb
We’ve been offering cutting-edge technologies for antibody discovery with OmniAb from Ligand Pharmaceuticals since 2012. OmniAb is known for being the only solution in the industry with multiple transgenic species of animals. Our offerings include:
Our team is engaged in ongoing efforts for helping our partners with designing antigens in conjunction with the use of our various animal offerings. Contact us to learn more about any of our technologies.
Frequently asked questions about designing antigens
We often receive inquiries from customers about our products. Here are answers to some of the most frequently asked questions regarding antigens and OmniAb:
What details do we need to provide to obtain antigens?
We’ll need to know about any special storage requirements for antigens, whether there are safety precautions we must observe, and what the culture protocol is (when using a cell line). Our scientists also must know about antigen format, whether whole cell, soluble protein, or DNA, for example.
How pure are the antigens?
We achieve a purity rate exceeding 90%.
What types of membrane proteins are suitable for an antigen?
A variety of formats are suitable, such as lipoparticles, nanodiscs, polymers, and proteoliposomes. Contact our team if you have specific membrane questions.
For additional technical details and more context about the work we do in regard to designing antigens, read Ab Initio Antigen Technology.
Multi-faceted antigen design leverages years of experience and a range of technologies
Use modeling and design, cloning, expression, purification, reconstitution, quality control of highly purified native membrane proteins and immunizations, and other antigen production methods.
Designer Antigens to Stimulate the Right Immune Response
Display antigen in particular conformations with protein or small molecule conformational chaperones. The high quality, stability, and variety of available formats maximize the chance of success in generating robust immune response with any of the OmniAb antibody platforms.